Non-alcoholic Steatohepatitis
Conditions
Brief summary
This is a Phase 1a/1b, randomised, double-blind, placebo-controlled single- and multiple-ascending dose study to evaluate the safety, tolerability, PK, and PD of GM-60106 in healthy adult male and female participants and otherwise healthy adults who have an increased BMI and markers of NAFLD.
Detailed description
The study consists of 3 parts: Part A (Single Ascending Dose \[SAD\]): Approximately 56 healthy participants will be enrolled into 7 cohorts and randomised to receive either GM-60106 or matching placebo at a ratio of 6:2 (GM-60106: placebo). Part B (Multiple Ascending Dose \[MAD\]): Approximately 24 healthy participants will be enrolled into 3 cohorts and randomised to receive either GM-60106 or matching placebo at a ratio of 6:2 (GM-60106: placebo). Part C (Multiple Ascending Dose \[MAD\]): Approximately 16 participants will be enrolled into 2 cohorts and randomised to receive either GM-60106 or matching placebo at a ratio of 6:2 (GM-60106: placebo). Cohorts will include otherwise healthy participants who have an increased BMI and markers of NAFLD. Part B and Part C will occur only after the Safety Monitoring Committee (SMC) has reviewed all blinded safety data as well as any available PK and PD data from MAD cohorts that have completed the assessment of doses equal to the proposed starting Part C (MAD) dose and a dose higher (including a minimum safety review interval of 10 days after dosing the sixth participant in the cohort) and recommends initiation. The study duration for each participant in Part A (SAD) is a maximum of 36 to 43 days, including a Screening period of up to 28 days, 1 day of single dosing, and a follow-up period of 7 days for most cohorts, and food effect assessment with a total treatment and follow-up period of 15 days for one of the SAD cohorts. The study duration for each participant in Part B (MAD) is a maximum of 49 days, including a Screening period of up to 28 days, 14 consecutive days of once daily dosing, and a follow-up period of 7 days. The study duration for each participant in Part C (MAD) is a maximum of 63 days, including a Screening period of up to 28 days, 28 consecutive days of once daily dosing, and a follow-up period of 7 days.
Interventions
DRUGGM-60106
The participants will receive a single oral dose between 2.5 to 100 mg for Part A (SAD), Part B (MAD) once daily for 14 days, and for Part C (MAD) once daily for 28 days.
OTHERPlacebo
Placebo-to-match GM-60106 capsules
Sponsors
Novotech (Australia) Pty Limited
JD Bioscience Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
Key inclusion Criteria: 1. Healthy adult males or females aged 18 to 55 years (inclusive) 2. Body weight ≥ 50 kg for males and ≥ 45 kg for females 3. Negative pregnancy test Key
Exclusion criteria
1. History or presence of clinically significant abnormalities or participants with psychosomatic disorders. 2. Positive test results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV) antibody. 3. Dosing in other clinical studies and treatment with a study drug within 3 months prior to IP administration. 4. Females who are pregnant or breastfeeding, or of childbearing potential who are not using effective non-hormonal contraception; men of childbearing potential who are unwilling to use physical methods of contraception during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess safety and tolerability of GM-60106 through incidence, nature, and severity of adverse events (AEs) | Part A: Up to 43 days, Part B: Up to 49 days, Part C: Up to 63 days |
Secondary
| Measure | Time frame |
|---|---|
| The pharmacokinetics (PK) of GM-60106. Plasma sample will be collected for PK assessment. Parameter: time to maximum concentration (Tmax) | Part A: Up to 43 days, Part B: Up to 49 days, Part C: Up to 63 days |
| The pharmacokinetics (PK) of GM-60106. Plasma sample will be collected for PK assessment. Parameter: Area under the curve (AUC) from time 0 to the last measurable concentration (AUC0-last) | Part A: Up to 43 days, Part B: Up to 49 days, Part C: Up to 63 days |
| The pharmacokinetics (PK) of GM-60106. Urine sample will be collected for PK assessment. Parameter: Cumulative amount of drug excreted in urine (Ae) | Part A: Up to 43 days, Part B: Up to 49 days, Part C: Up to 63 days |
| The pharmacokinetics (PK) of GM-60106. Plasma sample will be collected for PK assessment. Parameter: maximum concentration (Cmax) | Part A: Up to 43 days, Part B: Up to 49 days, Part C: Up to 63 days |
| The pharmacodynamics (PD) of GM-60106 through liver function test (aspartate aminotransferase [AST]) | Part A: Up to 43 days, Part B: Up to 49 days, Part C: Up to 63 days |
| The pharmacodynamics (PD) of GM-60106 through liver function test (alanine aminotransferase [ALT]) | Part A: Up to 43 days, Part B: Up to 49 days, Part C: Up to 63 days |
| The pharmacokinetics (PK) of GM-60106. Urine sample will be collected for PK assessment. Parameter: Renal clearance (CLr). | Part A: Up to 43 days, Part B: Up to 49 days, Part C: Up to 63 days |
Countries
Australia
Outcome results
None listed